Gynecologic Oncology
Advanced Ovarian Cancer: Platinum Sensitive
Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Cancer Types: Ovarian
Lines of Therapy: 3rd Line+ Metastatic
Advanced Ovarian Cancer: Platinum resistant
(EPIK-O) A Phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer
Cancer Types: GYN, Ovarian
Lines of Therapy: 2nd Line Metastatic, 3rd Line+ Metastatic
Advanced Ovarian Cancer: Platinum resistant
A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC)
Cancer Types: GYN, Ovarian
Lines of Therapy: 2nd Line Metastatic, 3rd Line+ Metastatic
Advanced Ovarian Cancer: Platinum resistant, Advanced Ovarian Cancer: Platinum sensitive
A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with olaparib in advanced ovarian cancer patients.
Cancer Types: GYN, Ovarian
Lines of Therapy: 2nd Line Metastatic, 3rd Line+ Metastatic
To schedule an appointment:
888-GYNONC1